



CREATHOR
VENTURE



Life Science Start-up Caprotec Bioanalytics Receives Additional Venture Capital Funding

Berlin, Germany, January 10, 2008 – Caprotec Bioanalytics GmbH receives a total of EUR 6 million (\$8.8M) in two rounds of financing from Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds and well-known private investors for further development and marketing of the Company’s proprietary CCMS platform technology for analyzing complex protein mixtures.. The private investors include Prof. Dr. Heinrich-Maria Schulte, Co-founder of Evotec AG and owner of the Wölbern Bank in Hamburg, Germany.

Caprotec’s CCMS (Capture Compound Mass Spectrometry) technology was developed by Prof. Dr. Hubert Köster, founder of Caprotec Bioanalytics GmbH as well as founder of Biosyntech GmbH, the first biotechnology company in Germany, co-founder of US company Milligen/Biosearch and founder of Sequenom (NASDAQ: SQNM).

“With the CCMS platform Prof. Köster has developed a technology that has enormous potential”, says Karlheinz Schmelig, Managing Director at Creathor Venture. “Moreover, as a former founder of several internationally successful biotech companies, Prof. Köster possesses the necessary entrepreneurial know-how.”

“The CCMS technology isolates proteins directly and selectively from a complex cellular environment,” says Prof. Köster, founder and CEO of Caprotec Bioanalytics. “Our platform closes a technological gap in the field of proteome analysis with its ability to be applied both in water-soluble and membrane protein mixtures.”

In the centre of the CCMS technology are small, tri-functional molecules called capture compounds (CCs). They enable a targeted isolation of proteins or protein classes directly from the complex biological sample. After isolation the captured proteins are identified and characterized by

mass spectrometry. CCMS technology is complementary to 2D gel electrophoresis and affinity chromatography. The CCs function as chemical probes detecting proteins directly in solution and thereby closing a technological gap. CCMS offers a general solution to investigate the interactions of small molecules (selectivity function) with the proteome. The demand in the protein analysis sector is rapidly increasing. According to experts the expected annual market growth is upwards of 20%. The isolation of certain proteins plays a key role in drug development, enabling the analysis of interactions between drug molecules and proteins. By conducting protein analysis diseases can be diagnosed at an early stage and therapies can be optimized.

About caprotec bioanalytics GmbH

caprotec bioanalytics GmbH is a Berlin-based biotech company focusing on the commercialization of its proprietary Capture Compound Mass Spectrometry™ (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called capture compounds (CCs). They enable a targeted isolation of proteins directly from complex biological samples. After isolation the captured proteins are identified and characterized by mass spectrometry. Providing a state-of-the-art platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in proteomics, drug development and the development of biomarkers. The technology is protected by a broad patent portfolio. caprotec bioanalytics was founded in 2006 by Prof. Dr. Hubert Köster, an acknowledged innovator and entrepreneur in the field of biotech. His track records include the foundation of Biosyntech, the first biotech company in Germany, the co-foundation of Milligen/Biosearch and the foundation of Sequenom Inc. As CEO and President of Sequenom he was responsible for one of the most successful US biotech IPOs at the NASDAQ.

After closing a financing round of EUR 6 million, caprotec bioanalytics started operations in January 2008 in Berlin-Adlershof. The Company is supported by an international scientific advisory board including one Nobel Laureate.

For further information please contact:

caprotec bioanalytics GmbH
Corporate Communications
Volmer Str. 5, 12489 Berlin
Tel.: +49 (0)30-6392-3990
Fax: +49 (0)30-6392-3989
info@caprotec.com
www.caprotec.com

About Creathor Venture

Creathor Venture invests in technology-oriented companies and entrepreneurs from the fields of life science, IT, telecommunication, new media, new materials, electronics, nanotechnology and clean tech. Creathor Venture's management team includes Dr. Gert Köhler, the founder of the former Technologieholding VC GmbH, as well as Ingo Franz and Karlheinz Schmelig. The team has been working in early-stage venture capital for 20 years. During that time more than 200 technology companies have been financed and over 20 IPOs as well as numerous trade sales have been conducted. Extraordinarily successful companies that the partners have managed from the first round of financing to IPO include Micronas (TechDax, SMI), SEZ (SMI), Intershop (Prime Segment), Infovista (NASDAQ, Nouveau Marché) and ITN Nanovation (Prime Segment).

Contact

Creathor Venture Management GmbH
Cornelia Koenig
Marienbader Platz 1
61348 Bad Homburg
Germany
Tel: +49 6172 13 97 20
Fax: +49 6172 13 97 229
Email: cornelia.koenig@creathor.de
www.creathor.de

About IBB Beteiligungsgesellschaft mbH

The IBB Beteiligungsgesellschaft mbH has been managing the VC Fonds Berlin since November 2004 and the newly founded VC Fonds Technologie Berlin as well as the VC Fonds Kreativwirtschaft Berlin since December 2007. The funds are financed by resources from the Investitionsbank Berlin (IBB) and from the Europäischer Fonds für regionale Entwicklung (EFRE), administrated by the Federal State of Berlin. Since 1997 the IBB Beteiligungsgesellschaft mbH, in consortia with partners has placed over EUR 470 million at the disposal of Berlin technology companies, whereof EUR 66 million were invested by the IBB Beteiligungsgesellschaft mbH as a lead, co-lead or co-investor.

Contact

IBB Beteiligungsgesellschaft mbH
Ute Mercker
Bundesallee 171
10715 Berlin
Tel.: +49 30 2125 3201
Fax: +49 30 2125 3202
E-Mail: venture@ibb-bet.de
www.ibb-bet.de

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements.